Credit: Shutterstock. Adlarity is a once-weekly transdermal formulation of donepezil that is designed to be worn for 7 days with consistent adhesion. The Food and Drug Administration (FDA) has ...

Donepezil oral tablet is available as a brand-name drug and a generic drug. Brand name: Aricept. Donepezil comes in two oral tablet forms: tablet and disintegrating tablet (ODT). Donepezil oral tablet ...

July 27, 2010 — The US Food and Drug Administration (FDA) has approved donepezil HCl 23-mg tablets (Aricept; Eisai, Inc and Pfizer, Inc) for the once-daily treatment of moderate to severe Alzheimer's ...

To learn more about the drug’s serious side effects, talk with your doctor or see donepezil’s prescribing information. The side effects of donepezil are generally the same regardless of age. But ...

- Indicated for Treatment of Moderate to Severe Alzheimer's Disease - DUBLIN and EMERYVILLE, Calif., Dec. 24, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) and Adamas Pharmaceuticals Inc. (NASDAQ: ADMS ...

Forest Laboratories announced that it has submitted a New Drug Application (NDA) for a fixed-dose combination (FDC) of memantine HCl extended release (ER), a receptor antagonist and donepezil HCl, ...

Donepezil is typically taken in the evening before bed, but in certain situations, your doctor may recommend taking your dose in the morning. Donepezil is a generic oral tablet or orally ...

The US Food and Drug Administration (US FDA) has given its final approval to Aurobindo Pharma Ltd. for 5mg and 10mg Donepezil Hydrochloride tablets. The US Food and Drug Administration (US FDA) has ...

City-based pharma major Dr Reddy’s Laboratories (DRL) on Saturday informed the bourses that it has launched Donepezil Hydrochloride tablets in the US market following the United States Food and Drug ...

Clinical trials have shown the benefits of cholinesterase inhibitors for the treatment of mild-to-moderate Alzheimer's disease. It is not known whether treatment benefits continue after the ...

- Indicated for Treatment of Moderate to Severe Alzheimer's Disease - DUBLIN and EMERYVILLE, Calif., Dec. 24, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) and Adamas Pharmaceuticals Inc. (NASDAQ: ADMS ...